134 related articles for article (PubMed ID: 2938729)
41. Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma. A Southwest Oncology Group study.
Vance RB; Crowley JJ; Macdonald JS; Ahmann FR
Invest New Drugs; 1991 Feb; 9(1):73-5. PubMed ID: 1851143
[TBL] [Abstract][Full Text] [Related]
42. [Antitumor spectrum of TUT-7 on rat ascitic hepatoma].
Satoh H; Taguchi H; Yahagi S
Gan To Kagaku Ryoho; 1990 Feb; 17(2):287-91. PubMed ID: 2137321
[TBL] [Abstract][Full Text] [Related]
43. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
Warrell RP; Arlin ZA; Kempin SJ; Young CW
Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
[TBL] [Abstract][Full Text] [Related]
44. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
[TBL] [Abstract][Full Text] [Related]
45. Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer.
Kennedy MJ; Donehower RC; Grochow LB; Ettinger DS; Fetting JH; Abeloff MD
Invest New Drugs; 1990 Aug; 8(3):289-94. PubMed ID: 2148742
[TBL] [Abstract][Full Text] [Related]
46. A phase II study of menogaril (NSC-269148) in colorectal carcinoma. A Southwest Oncology Group study.
Whitehead RP; Earhart RH; Fleming T; Goodman P; Macdonald JS; Pollock T; Ungerleider JS
Invest New Drugs; 1990 Aug; 8(3):295-7. PubMed ID: 2148743
[TBL] [Abstract][Full Text] [Related]
47. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
48. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
49. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
50. A phase II evaluation of menogaril in cisplatin-refractory advanced ovarian carcinoma. A collaborative trial of the North Central Cancer Treatment Group and the Mayo Clinic.
Long HJ; Laurie JA; Wieand HS; Edmonson JH; Levitt R; Krook JE; Abu-Ghazaleh S
Cancer; 1991 Aug; 68(4):730-2. PubMed ID: 1830238
[TBL] [Abstract][Full Text] [Related]
51. Menogaril: a new anthracycline agent entering clinical trials.
McGovren JP; Nelson KG; Lassus M; Cradock JC; Plowman J; Christopher JP
Invest New Drugs; 1984; 2(4):359-67. PubMed ID: 6239835
[TBL] [Abstract][Full Text] [Related]
52. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin.
Chandrasekaran B; Dimling J; Capizzi RL
Cancer Treat Rep; 1987 Feb; 71(2):195-6. PubMed ID: 2948640
[TBL] [Abstract][Full Text] [Related]
53. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
54. Phase I trial of mitoxantrone by 24-hour continuous infusion.
Anderson KC; Garnick MB; Meshad MW; Cohen GI; Pegg WJ; Frei E; Israel M; Modest E; Canellos GP
Cancer Treat Rep; 1983 May; 67(5):435-8. PubMed ID: 6850662
[TBL] [Abstract][Full Text] [Related]
55. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
Young CW; Fanucchi MP; Declan Walsh T; Baltzer L; Yaldaei S; Stevens YW; Gordon C; Tong W; Rifkind RA; Marks PA
Cancer Res; 1988 Dec; 48(24 Pt 1):7304-9. PubMed ID: 3191501
[TBL] [Abstract][Full Text] [Related]
56. Phase II evaluation of menogaril in patients with advanced cervical carcinoma. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.
LONG HJ; Wieand HS; Foley JF; Niedringhaus RD; Laurie JA; Morton RF; Goldberg RM; Mailliard JA; Malkasian GD; Edmonson JH
Invest New Drugs; 1991 Nov; 9(4):349-51. PubMed ID: 1839536
[TBL] [Abstract][Full Text] [Related]
57. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
[TBL] [Abstract][Full Text] [Related]
58. Failure of aclacinomycin and 7-con-O-methylnogarol (7-OMEN) to decrease cardiac guanylate cyclase activity.
Levey BA; Ruiz E; Rogerson B; Lehotay DC; Levey GS
Cancer Treat Rep; 1980; 64(10-11):1127-8. PubMed ID: 6109566
[No Abstract] [Full Text] [Related]
59. Cell kill kinetics of several nogalamycin analogs and adriamycin for Chinese hamster ovary, L1210 leukemia, and B16 melanoma cells in culture.
Bhuyan BK; Blowers CL; Crampton SL; Shugars KD
Cancer Res; 1981 Jan; 41(1):18-24. PubMed ID: 7448758
[TBL] [Abstract][Full Text] [Related]
60. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942).
Von Hoff DD; Myers JW; Kuhn J; Sandbach JF; Pocelinko R; Clark G; Coltman CA
Cancer Res; 1981 Aug; 41(8):3118-21. PubMed ID: 6265075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
